Skip to main content

Table 3 Adaptation to normoxia (N) is accompanied by an evolutionary trade-off that is suppressed by cysteine under CoCl2 mimicked hypoxia (H) in ES2 cells

From: Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer

A.

Treatments – cell death analysis (48 h)

Tukey test sig.

ES2-AN vs ES2-AH

0.008

ES2-ANC vs ES2-AH

0.001

ES2-AHC vs ES2-AH

0.001

ES2-NN vs ES2-NH

0.000

ES2-NNC vs ES2-NH

0.000

ES2-NHC vs ES2-NH

0.000

B.

Treatments – cell death analysis (48 h)

Tukey test sig.

ES2-NNC vs ES2-HNC

0.030

ES2-NH vs ES2-AH

0.034

ES2-NH vs ES2-HH

0.001

ES2-HH vs ES2-AH

0.016

C.

Treatments – cell death analysis (48 h)

Tukey test sig.

OVCAR3-AN vs OVCAR3-AH

0.000

OVCAR3-ANC vs OVCAR3-AH

0.000

OVCAR3-AHC vs OVCAR3-AH

0.003

OVCAR3-NH vs OVCAR3-NN

0.003

OVCAR3-NH vs OVCAR3-NNC

0.004

D.

Treatments – cell death analysis (48 h)

Tukey test sig.

OVCAR3-AN vs OVCAR3-HN

0.002

OVCAR3-NN vs OVCAR3-HN

0.009

OVCAR3-ANC vs OVCAR3-NNC

0.004

OVCAR3-ANC vs OVCAR3-HNC

0.000

OVCAR3-NNC vs OVCAR3-HNC

0.001

OVCAR3-AH vs OVCAR3-NH

0.036

OVCAR3-HH vs OVCAR3-NH

0.008